Loading clinical trials...
Loading clinical trials...
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 7 - Belantamab Mafodotin, Nirogacestat, Pomalidomide, and Dexamethasone in Combination
Conditions
Interventions
Belantamab mafodotin
Nirogacestat
+2 more
Locations
10
Brazil
GSK Investigational Site
Salvador, Estado de Bahia, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
Oslo, Norway
Start Date
August 31, 2022
Primary Completion Date
April 17, 2025
Completion Date
March 11, 2027
Last Updated
September 2, 2025
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06383143
NCT06057402
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions